Peringatan Keamanan

LD50 of 6480mg/kg observed in rats.MSDS

Gabexate

DB12831

small molecule investigational

Deskripsi

Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.A19218,A19219,A19220

Struktur Molekul 2D

Berat 321.377
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

640 Data
Apixaban Apixaban may increase the anticoagulant activities of Gabexate.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Gabexate.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Gabexate.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Gabexate is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Gabexate.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Gabexate.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Obinutuzumab.
Rivaroxaban Gabexate may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Gabexate.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Gabexate.
Urokinase Urokinase may increase the anticoagulant activities of Gabexate.
Vitamin E Vitamin E may increase the anticoagulant activities of Gabexate.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Gabexate.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Gabexate.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Gabexate.
Quinine The therapeutic efficacy of Gabexate can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Gabexate can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Gabexate.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Gabexate.
Pentoxifylline The therapeutic efficacy of Gabexate can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Gabexate.
Levocarnitine The therapeutic efficacy of Gabexate can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Gabexate.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Gabexate.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Gabexate.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Gabexate.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Gabexate.
Quinestrol Quinestrol may decrease the anticoagulant activities of Gabexate.
Hexestrol Hexestrol may decrease the anticoagulant activities of Gabexate.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Gabexate.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Gabexate.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Gabexate.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Gabexate.
Zeranol Zeranol may decrease the anticoagulant activities of Gabexate.
Equol Equol may decrease the anticoagulant activities of Gabexate.
Methallenestril Methallenestril may decrease the anticoagulant activities of Gabexate.
Epimestrol Epimestrol may decrease the anticoagulant activities of Gabexate.
Moxestrol Moxestrol may decrease the anticoagulant activities of Gabexate.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Gabexate.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Gabexate.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Gabexate.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Gabexate.
Biochanin A Biochanin A may decrease the anticoagulant activities of Gabexate.
Formononetin Formononetin may decrease the anticoagulant activities of Gabexate.
Estriol Estriol may decrease the anticoagulant activities of Gabexate.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Gabexate.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Gabexate.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Gabexate.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Gabexate.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Gabexate.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Gabexate.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Gabexate.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Gabexate.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Gabexate.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Gabexate.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Gabexate.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Gabexate.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Gabexate.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Gabexate.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Gabexate.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Gabexate.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Gabexate.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Gabexate.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Gabexate.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Gabexate.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Gabexate.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Gabexate.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Gabexate.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Gabexate.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Gabexate.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Gabexate.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Gabexate.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Gabexate.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Gabexate.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Gabexate.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Gabexate.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Gabexate.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Gabexate.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Gabexate.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Gabexate.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Gabexate.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Gabexate.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Gabexate.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Gabexate.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Gabexate.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Gabexate.

Target Protein

Plasma kallikrein KLKB1
Prothrombin F2
Plasminogen PLG

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12649382
    Yuksel M, Okajima K, Uchiba M, Okabe H: Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther. 2003 Apr;305(1):298-305.
  • PMID: 3104578
    Menegatti E, Bolognesi M, Scalia S, Bortolotti F, Guarneri M, Ascenzi P: Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. J Pharm Sci. 1986 Dec;75(12):1171-4.
  • PMID: 143965
    Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22.
  • PMID: 22911782
    Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24.
  • PMID: 24507023
    Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP: Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037.
  • PMID: 23812506
    Kim SC, Yang HR: Clinical efficacy of gabexate mesilate for acute pancreatitis in children. Eur J Pediatr. 2013 Nov;172(11):1483-90. doi: 10.1007/s00431-013-2068-6. Epub 2013 Jun 29.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul